Graham Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Graham Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Buy	+10,022	New	+$233K	﹤0.01%	950
2025 Q4	–	Sell	-35,278	Closed	-$665K	–	1220
2025 Q3	$665K	Sell	35,278 -36,342	-51%	-$573K	0.01%	514
2025 Q2	$1M	Buy	71,620 +34,003	+90%	+$477K	0.02%	579
2025 Q1	$588K	Buy	37,617 +10,780	+40%	+$152K	0.01%	739
2024 Q4	$374K	Buy	26,837 +4,551	+20%	+$49.9K	0.01%	842
2024 Q3	$207K	Sell	22,286 -43,879	-66%	-$433K	﹤0.01%	900
2024 Q2	$615K	Buy	66,165 +52,699	+391%	+$477K	0.01%	521
2024 Q1	$133K	Sell	13,466 -48,951	-78%	-$365K	﹤0.01%	946
2023 Q4	$202K	Buy	+62,417	New	+$170K	﹤0.01%	841

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Graham Capital Management's ARQT Position: Q2 2026 in Review

Graham Capital Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 10,022 shares worth $263K. The stake represents ﹤0.01% of the portfolio and ranks #950 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in ARQT as recently as Q3 2025.

Graham Capital Management first reported a position in ARQT in Q4 2023 and has held it in 9 quarters since. The position peaked at $1M in Q2 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Graham Capital Management held 10,022 shares of Arcutis Biotherapeutics worth $263K as of Q2 2026.
Arcutis Biotherapeutics was a new Graham Capital Management position in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #950 holding.
Graham Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 9 quarters since.
Graham Capital Management's Arcutis Biotherapeutics position peaked at $1M in Q2 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.